The cladribine conundrum: Deciphering the drug's mechanism of action

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 1, 2010, Pages 75-81

  Hentosh, Patricia ^a   Peffley, Dennis M ^b  

^a OLD DOMINION UNIVERSITY   (United States)

^b Kronos Science Laboratories   (United States)

Author keywords

Autophagy; Cancer therapeutic; Cell death; Cladribine; Cytotoxicity; Mechanism of action; Nucleoside analogue

Indexed keywords

2 FLUORO 9 BETA DEXTRO ARABINOFURANOSYLADENINE 5' TRIPHOSPHATE; ANTILEUKEMIC AGENT; CLADRIBINE; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG; VIDARABINE TRIPHOSPHATE;

APOPTOSIS; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; HUMAN; IN VITRO STUDY; MEDICAL RESEARCH; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL SURVIVAL; CLADRIBINE; HUMANS; LEUKEMIA;

EID: 72949124131     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903393745     Document Type: Review

References (65)

1. Fanta PT, Saven A. Hairy cell leukemia. Cancer Treat Res 2008;142:193-209
2. Greyz N, Saven A. Cladribine: From the bench to the bedside-focus on hairy cell leukemia. Expert Rev Anticancer Ther 2004;4:745-757
3. Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001;19:2804-2811
4. Robak T. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: Facts and controversies. Drugs Aging 2005;22:983-1012
5. Tobinai K, Watanabe T, Tanimoto K, et al. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. Cancer Sci 2009;100:1344-1350
6. Tondini C, Balzarotti M, Rampinelli I, et al. Fludarabine and cladribine in relapsed/refractory low-grade non-hodgkin's lymphoma: A phase II randomized study. Ann Oncol 2000;11:231-233
7. Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007;23:2667-2676
8. Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008;29:558-565
9. Martinez-Rodriguez JE, Cadavid D, Wolansky LJ, et al. Cladribine in aggressive forms of multiple sclerosis. Eur J Neurol 2007;14:686-689
10. Rubnitz JE, Crews KR, Pounds S, et al. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: Results of the St Jude AML97 trial. Leukemia 2009;23:1410-1416
11. Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: A final report of the Polish Adult Leukemia Group. Eur J Haematol 2008;80:115-126
12. Korycka A, Robak T. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro. Leuk Lymphoma 2003;44:1549-1555
13. Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma 2003;44:391-409
14. Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008;113:108-116
15. Robak T, Smolewski P, Cebula B, et al. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 2007;79:107-113
16. Walker AR, Komrokji RS, Ifthikharuddin J, et al. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res 2008;32:1830-1836
17. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007;110:2240-2247
18. Parker WB, Bapat AR, Shen JX, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 1988;34:485-491
19. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980;77:6865-6869
20. Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989;49:6923-6928
21. Fyrberg A, Albertioni F, Lotfi K. RNAi depletion of deoxycytidine and deoxyguanosine kinase in human leukemic CEM cells. Nucleosides Nucleotides Nucleic Acids 2008;27:712-719
22. Lotfi K, Juliusson G, Albertioni F. Pharmacological basis for cladribine resistance. Leuk Lymphoma 2003;44:1705-1712
23. Hentosh P, Koob R, Blakley RL. Incorporation of 2-halogeno-2¢- deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem 1990;265:4033-4040
24. Yuh SH, Tibudan M, Hentosh P. Analysis of 2-chloro-2¢-deoxyadenosine incorporation into cellular DNA by quantitative polymerase chain reaction. Anal Biochem 1998;262:1-8
25. Hartman WR, Hentosh P. The antileukemia drug 2-chloro-2¢- deoxyadenosine: An intrinsic transcriptional antagonist. Mol Pharmacol 2004;65:227-234
26. Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985;75:377-383
27. Mellon I, Bohr VA, Smith CA, et al. Preferential DNA repair of an active gene in human cells. Proc Natl Acad Sci USA 1986;83:8878-8882
28. Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res 2008;32:1573-1581
29. Spurgeon S, Yu M, Phillips JD, et al. Cladribine: Not just another purine analogue? Expert Opin Investig Drugs 2009;18:1169-1181
30. Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983;62:737-743
31. Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2¢-arabino-fluoro-2¢- deoxyadenosine. Proc Natl Acad Sci USA 1992;89:2970-2974
32. Huang MC, Ashmun RA, Avery TL, et al. Effects of cytotoxicity of 2-chloro-2¢-deoxyadenosine and 2-bromo-2¢-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics. Cancer Res 1986;46:2362-2368
33. Kearns CM, Blakley RL, Santana VM, et al. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 1994;54:1235-1239
34. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2¢- deoxyadenosine in humans. Cancer Res 1991;51:5570-5572
35. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992;340:952-956
36. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2¢-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995;1:385-390
37. Albertioni F, Lindemalm S, Reichelova V, et al. Pharmacokinetics of cladribine in plasma and its 5¢-monophosphate and 5¢-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res 1998;4:653-658
38. Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2¢-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 1993;81:143-150
39. Zinzani PL, Tosi P, Visani G, et al. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994;47:301-306 (Pubitemid 24372285)
40. Nomura Y, Inanami O, Takahashi K, et al. 2-Chloro-2¢-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4. Leukemia 2000;14:299-306
41. Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 2000;275:29-34
42. Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2¢-deoxyadenosine 5¢-triphosphate and cytochrome c. Proc Natl Acad Sci USA 1998;95:9567-9571
43. Gandhi V, Kemena A, Keating MJ, et al. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 1993;10:49-56
44. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537-3543
45. Cardoen S, Van Den Neste E, Smal C, et al. Resistance to 2-chloro-2¢-deoxyadenosine of the human B-cell leukemia cell line EHEB. Clin Cancer Res 2001;7:3559-3566
46. Conrad DM, Robichaud MR, Mader JS, et al. 2-Chloro-2¢- deoxyadenosine-induced apoptosis in T leukemia cells is mediated via a caspase-3-dependent mitochondrial feedback amplification loop. Int J Oncol 2008;32:1325-1333
47. Marzo I, Perez-Galan P, Giraldo P, et al. Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J 2001;359:537-546
48. Smal C, Lisart S, Maerevoet M, et al. Pharmacological inhibition of the MAPK/ ERK pathway increases sensitivity to 2-chloro-2¢-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB. Biochem Pharmacol 2007;73:351-358
49. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: An emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 2008;76:947-957
50. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-2614
51. Rebbaa A, Zheng X, Chou PM, et al. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 2003;22:2805-2811
52. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-346
53. Chandra J, Mansson E, Gogvadze V, et al. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood 2002;99:655-663
54. Hentosh P, Tibudan M. 2-Chloro-2¢-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function. Mol Pharmacol 1997;51:613-619
55. Castejon R, Vargas JA, Briz M, et al. Induction of apoptosis by 2-chlorodeoxyadenosine in B cell chronic lymphocytic leukemia. Leukemia 1997;11:1253-1257
56. Stachnik K, Grieb P, Skierski JS. Cytotoxic effects of cladribine and tezacitabine toward HL-60. Acta Biochim Pol 2005;52:561-565
57. Lee MW, Kim WJ, Beardsley DI, et al. N-methyl-N'-nitro-N-nitrosoguanidine activates multiple cell death mechanisms in human fibroblasts. DNA Cell Biol 2007;26:683-694
58. Stephenson LM, Miller BC, Ng A, et al. Identification of Atg5-dependent transcriptional changes and increases in mitochondrial mass in Atg5-deficient T lymphocytes. Autophagy 2009;5:625-635
59. Ideo A, Hashimoto K, Shimada J, et al. Type of cell death induced by alpha-trifluoromethyl acyloins in oral squamous cell carcinoma. Anticancer Res 2009;29:175-181
60. Pettitt AR, Cawley JC. Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia. Br J Haematol 2000;109:800-804
61. Laane E, Tamm KP, Buentke E, et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009;16:1018-1029
62. Chen YJ, Huang WP, Yang YC, et al. Platonin induces autophagy-associated cell death in human leukemia cells. Autophagy 2009;5:173-183
63. Crazzolara R, Bradstock KF, Bendall LJ. RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 2009;5:727-728
64. Ghavami S, Asoodeh A, Klonisch T, et al. Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. J Cell Mol Med 2008;12:1005-1022
65. Yokoyama T, Miyazawa K, Naito M, et al. Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy 2008;4:629-640